Provide feedbackProvide feedback
Home :: Hematology/Oncology

Addition of radiotherapy to endocrine therapy has little negative long-term effect on QOL among men with prostate cancer, study shows

Friday, April 24 2009 | Comments
Evidence Grade 2 What's This?

The substantial benefits of adding radiotherapy to endocrine treatment for locally advanced prostate cancer outweigh significant increases in some treatment-related symptoms, research indicates, particularly since the symptoms often associated with radiotherapy appear to have little additional effect on quality of life (QOL) after 4 years. Researchers analyzed self-reported patient data from a previous open-label Phase III trial of 872 men with locally advanced prostate cancer who had...

The substantial benefits of adding radiotherapy to endocrine treatment for locally advanced prostate cancer outweigh significant increases in some treatment-related symptoms, research indicates, particularly since the symptoms often associated with radiotherapy appear to have little additional effect on quality of life (QOL) after 4 years.

Researchers analyzed self-reported patient data from a previous open-label Phase III trial of 872 men with locally advanced prostate cancer who had received 3 months of total androgen blockade followed by either continuous endocrine treatment or the same endocrine treatment plus radiotherapy 3 months after study entry.

Disease-specific urinary, bowel, and sexual function symptoms, as well as QOL, were the primary outcome measures for this analysis.

Significantly more patients in the radiation group reported more moderate to severe urinary bother than in the endocrine-only group. Reports of bowel symptoms were also significantly higher in the radiation group.

Large proportions of both groups reported erectile dysfunction, although the condition was reported by significantly more patients in the combined group than in the endocrine-only group (85% vs 72%; P=.0002).

At 4 years, however, the only QOL measure that differed significantly between the groups was social function, which was decreased among the subjects receiving radiotherapy.

"The addition of radiotherapy to endocrine treatment led to significant worsening of some symptoms. Clinically significant differences in radiotherapy-induced symptoms between treatment groups were expected, but they were also small," the authors concluded. "Relative to the benefit on overall survival, death from prostate cancer, and delayed prostate-specific antigen relapse, the increase of symptoms with the addition of radiotherapy seems small and has little effect on quality of life 4 years after treatment." (Fransson P, et al. Lancet Oncol 2009;10:370-380.)

Latest News

PSA screening controversy increases with release of mortality studies with conflicting results, modest benefits Verusmed

Wednesday, April 08 2009 | Comments
Evidence Grade 1 What's This?
The controversy surrounding prostate-specific antigen (PSA) screening is only going to increase following the release of data from 2 studies that showed either no mortality benefit from PSA screening or a small benefit that was overshadowed by overdiagnosis and overtreatment concerns.

In the first study, the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial, no difference was seen in mortality rates between patients who underwent PSA screening and those who...
Tags: Prostate Cancer


No association found between dietary intake of fat, increased risk of renal cell carcinoma, study shows Verusmed

Tuesday, January 13 2009 | Comments
Evidence Grade 2 What's This?
No association between intakes of fat and protein, including red meat, processed meat, poultry, and seafood, and the risk of renal cell cancer was evident in a recent analysis.

The upward trend of kidney cancer incidence cannot be fully explained by improved detection techniques, but may, in part, be due to lifestyle changes, including increased obesity and hypertension, the authors explained. Studies done on the association of fat intake and the risk of kidney cancer have...


Systematic pelvic lymphadenectomy improves surgical staging, but not survival in patients with early-stage endometrial cancer, study shows Verusmed

Friday, December 26 2008 | Comments
Evidence Grade 2 What's This?
The addition of pelvic systematic lymphadenectomy to standard hysterectomy with bilateral salpingo-oophorectomy in patients with early-stage endometrial cancer results in a statistically significant improvement of surgical staging with no improvement of disease-free or overall survival, researchers recently reported.

The authors randomized 514 eligible patients with preoperative FIGO (International Federation of Gynecology and Obstetrics) stage I endometrial carcinoma to...

NSAIDs safe, effective after prostatectomy, new data reveal Verusmed

Friday, December 26 2008 | Comments
Evidence Grade 2 What's This?
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a safe alternative for postoperative analgesia after radical retrospective prostatectomy (RRP) and do not increase the risk of postoperative hemorrhage, according to recently published study results.

Many urologists are reluctant to use NSAIDs after RRP because of hemorrhagic complications, even though there have been no prospective, randomized studies examining the effects of NSAIDs on postoperative bleeding after RRP, the...
Tags: Prostate Cancer, Prostate Cancer






Hematology/Oncology Conference Coverage